Clinical Trial Update: CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of CD8+ antigen-specific T cells with cyclophosphamide, aldesleukin, and ipilimumab for metastatic melanoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• CD8+ antigen-specific T cells
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• ipilimumab (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7 | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08